CG Labz
Peptide Library / Metabolic / Weight Management

Cagrilintide

Long-acting Amylin Analog

Cagrilintide Research Protocol

Complete Research Guide 4 min read2 peer-reviewed references

Quickstart Overview

Cagrilintide is a long-acting amylin analog engineered for once-weekly dosing. Amylin is a pancreatic hormone co-secreted with insulin that promotes satiety and slows gastric emptying; cagrilintide is studied alone and paired with semaglutide (CagriSema) for weight management.

Reconstitution
Add 2.0 mL bacteriostatic water to a 5 mg vial → 2.5 mg/mL
Clinical Titration
0.3 → 0.6 → 1.2 → 2.4 mg
Measuring Reference
At 2.5 mg/mL: 0.3 mg = 0.12 mL = 12 units
Frequency
Once weekly
Half-life
~7 days
Route (studies)
Subcutaneous

Scientific Data

Molecular Formula
—
Molecular Weight
3751 Da
Sequence
Acylated amylin analog
Sequence Length
20
CAS
Research compound
Peptide Family
Amylin mimetic
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 5 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
2.50 mg/mL
Draw Volume
0.120 mL
Syringe Units
12.0 U
Doses / Vial
16

Units assume a U-100 insulin syringe (100 units = 1 mL). Titrate slowly; amylin agonists are well tolerated when stepped up gradually.

Frequency: Once weekly

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 20-week protocol at approximately 300 mcg per day.

Peptide (5 mg vials)
Estimate vials from total mass: 300 mcg/day × 140 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model amylin-receptor satiety effects on appetite and body weight.
Schedule
Weekly with gradual titration.
Dose Range
0.3 mg to 2.4 mg weekly.

Dosing Protocol

Weeks 1–4
0.3 mg weekly
Weeks 5–8
0.6 mg weekly
Weeks 9–12
1.2 mg weekly
Maintenance
1.7–2.4 mg weekly as tolerated
Frequency
Once weekly
Timing
Same day weekly; titrate to limit nausea

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Amylin analogs are generally well tolerated; nausea is the main titration-limiting effect.
  • Often studied in combination with semaglutide rather than as monotherapy.

How This Works

Cagrilintide activates amylin and calcitonin receptors in the hindbrain to enhance satiety, slow gastric emptying and reduce food intake through a pathway complementary to (and additive with) GLP-1 agonism. An acyl side chain provides albumin binding for a once-weekly half-life. In combination with semaglutide the two hormones target distinct satiety circuits, producing greater weight loss than either alone.

Potential Benefits & Side Effects

Reported in research
  • Dose-dependent appetite suppression and weight reduction
  • Additive effect with GLP-1 agonists (CagriSema combination)
  • Slowed gastric emptying and increased satiety
  • Favourable tolerability relative to dose in trials
Possible considerations
  • Nausea and GI effects (dose-dependent)
  • Injection-site reactions
  • Appetite suppression can reduce protein intake
  • Human data still emerging

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] New England Journal of Medicine
    Enebo L.B. et al. Cagrilintide plus semaglutide for obesity.
    View Source
  2. [2] The Lancet
    Lau D.C.W. et al. Once-weekly cagrilintide for weight management.
    View Source